0000000001194713

AUTHOR

Luca Durelli

showing 7 related works from this author

Treatment of multiple sclerosis patients after 24 Natalizumab doses: a prospective observational study: the TY-STOP

2014

Multiple Sclerosis Natalizumab Ty-STOPSettore MED/26 - Neurologia
researchProduct

No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML

2017

Objective:To examine retrospectively the effects of plasmapheresis (PLEX) on the survival and clinical outcomes of patients with multiple sclerosis (MS) and natalizumab (NTZ)–associated progressive multifocal leukoencephalopathy (PML).Methods:The medical literature was searched for the terms natalizumab and progressive multifocal leukoencephalopathy. A total of 193 international and 34 Italian NTZ-PML cases were included. Clinical outcome was determined by comparing the patients' clinical status at PML diagnosis with status after PML resolution. The effects on survival and clinical outcome of PLEX, sex, age, country, pre-PML Expanded Disability Status Scale score, NTZ infusion number, prior…

OncologyMaleJC virus030204 cardiovascular system & hematologymedicine.disease_causeLeukoencephalopathyDisability Evaluationneurology (clinical); progressive multifocal leukoencephalopathy; reconstitution inflammatory syndrome; multiple-sclerosis0302 clinical medicineNatalizumabImmunologic FactorLeukoencephalopathyRetrospective StudieMultiple SclerosiMedicinePlasmapheresiAdult; Disability Evaluation; Female; Humans; Immunologic Factors; Leukoencephalopathy Progressive Multifocal; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Plasmapheresis; PubMed; Retrospective Studies; Statistics Nonparametric; Treatment OutcomeProgressive multifocal leukoencephalopathyNatalizumabStatisticsLeukoencephalopathy Progressive MultifocalPlasmapheresisMiddle AgedTreatment OutcomeFemaleSettore MED/26 - Neurologiamedicine.drugHumanAdultmedicine.medical_specialtyPubMedMultiple SclerosisProgressive MultifocalStatistics Nonparametric03 medical and health sciencesImmune reconstitution inflammatory syndromeInternal medicineHumansImmunologic FactorsNonparametricprogressive multifocal leukoencephalopathy multiple sclerosis side effectRetrospective StudiesExpanded Disability Status Scalebusiness.industryMultiple sclerosisRetrospective cohort studymedicine.diseaseImmunologyNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

Prognostic indicators in pediatric clinically isolated syndrome

2017

To assess prognostic factors for a second clinical attack and a first disability worsening event in pediatric clinically isolated syndrome (pCIS) suggestive of Multiple Sclerosis (MS) patients. Objective: To assess prognostic factors for a second clinical attack and a first disability-worsening event in pediatric clinically isolated syndrome (pCIS) suggestive of multiple sclerosis (MS) patients. Methods: A cohort of 770 pCIS patients was followed up for at least 10 years. Cox proportional hazard models and Recursive Partitioning and Amalgamation (RECPAM) tree-regression were used to analyze data. Results: In pCIS, female sex and a multifocal onset were risk factors for a second clinical att…

RegistrieMaleMultiple SclerosisAdolescentAdolescent; Age of Onset; Child; Demyelinating Diseases; Female; Follow-Up Studies; Humans; Male; Multiple Sclerosis; Prognosis; Retrospective Studies; Risk Factors; Disease Progression; Registries; Neurology; Neurology (clinical)PrognosiONSET MULTIPLE-SCLEROSISCHILDHOODCHILDRENPARACLINICAL FEATURESDISABILITY PROGRESSIONNOFollow-Up StudieRisk FactorsRetrospective Studieprognostic indicatorsMultiple Sclerosipediatric multiple sclerosis prognosis indicatorsHumansRegistriesAge of OnsetChildOPTIC NEURITISRetrospective StudiesRisk FactorDemyelinating DiseaseNATURAL-HISTORYPrognosismultiple sclerosis clinically isolated syndrome prognostic indicatorsNeurologyTRANSVERSE MYELITISclinically isolated syndromeINTERFERON BETA-1BDisease ProgressionSettore MED/26 - NeurologiaFemaleNeurology (clinical)FOLLOW-UPDemyelinating DiseasesFollow-Up StudiesHuman
researchProduct

To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy

2016

OBJECTIVE: To retrospectively analyze the effect of plasma exchange (PLEX; yes = PLEX+ , no = PLEX- ) and steroids administration timing (prophylactically [proST] or therapeutically [therST]) on the longitudinal clinical course of patients with natalizumab-related progressive multifocal leukoencephalopathy (PML) and full-blown immune reconstitution inflammatory syndrome (PML-IRIS). METHODS: Clinical and radiological data of 42 Italian patients with PML were analyzed. Patient's data are available until 12 months after PML diagnosis. PLEX and steroids treatment as time-dependent covariates were entered in: (1) a Cox model to investigate their impact on full-blown PML-IRIS latency; (2) an anal…

AdultMaleAdult; Databases Factual; Disability Evaluation; Female; Humans; Immune Reconstitution Inflammatory Syndrome; Leukoencephalopathy Progressive Multifocal; Male; Plasma Exchange; Retrospective Studies; Steroids; Young Adult; Neurology; Neurology (clinical)Adult; Databases Factual; Disability Evaluation; Female; Humans; Immune Reconstitution Inflammatory Syndrome; Leukoencephalopathy Progressive Multifocal; Male; Plasma Exchange; Retrospective Studies; Steroids; Young AdultDatabases FactualPlasma ExchangeLeukoencephalopathy Progressive MultifocalProgressive MultifocalDatabasesDisability EvaluationYoung AdultNeurologyLeukoencephalopathyImmune Reconstitution Inflammatory SyndromeRetrospective StudieHumansSteroidsFemaleSettore MED/26 - NeurologiaNeurology (clinical)SteroidFactualRetrospective StudiesHuman
researchProduct

Natalizumab Discontinuation after the 24th Course: Which Is Way? The TY-STOP Study

2013

Multiple SclerosisNatalizumab multiple sclerosisNatalizumabSettore MED/26 - NeurologiaMRi
researchProduct

The still under-investigated role of cognitive deficits in PML diagnosis

2017

Background: Despite cognitive deficits frequently represent the first clinical manifestations of Progressive Multifocal Leukoencephalopathy (PML) in Natalizumab-treated MS patients, the importance of cognitive deficits in PML diagnosis is still under-investigated. The aim of the current study is to investigate the cognitive deficits at PML diagnosis in a group of Italian patients with PML. Methods: Thirty-four PML patients were included in the study. The demographic and clinical data, the lesion load and localization, and the longitudinal clinical course was compared between patients with (n = 13) and without (n = 15) cognitive deficit upon PML suspicion (the remaining six patients were asy…

0301 basic medicinecognitionmedicine.medical_specialtyPediatricscognition; italian database; natalizumab; neuropsychological impairment; progressive multifocal leukoencephalopathy; neurology (clinical); neurology; immunology; immunology and allergy; natalizumab; cognition; neuropsychological impairment; italian databaseNeurologySettore MED/17 - Malattie InfettiveAsymptomaticApraxiaprogressive multifocal leukoencephalopathyimmunology03 medical and health sciences0302 clinical medicinenatalizumabitalian databasemedicineDementiaimmunology and allergyPsychiatryCognitive deficitneurology (clinical)Progressive multifocal leukoencephalopathyneurologyNeuropsychologyCognitionProgressive multifocal leukoencephalopathy Natalizumab Cognition Neuropsychological impairment Italian databasemedicine.disease030104 developmental biologyCognition; Italian database; Natalizumab; Neuropsychological impairment; Progressive multifocal leukoencephalopathyCognition Italian database Natalizumab Neuropsychological impairment Progressive multifocal leukoencephalopathyCognition; Italian database; Natalizumab; Neuropsychological impairment; Progressive multifocal leukoencephalopathy; Immunology and Allergy; Immunology; Neurology; Neurology (clinical)Settore MED/26 - Neurologiamedicine.symptomPsychologyneuropsychological impairment030217 neurology & neurosurgery
researchProduct

Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observation…

2014

Importance The evaluation of therapeutic choices is needed after 24 doses of natalizumab in patients with multiple sclerosis (MS). Objective To evaluate the effect of therapeutic choices on the mean annualized relapse rate and on magnetic resonance imaging MS activity after 24 doses of natalizumab in patients with relapsing-remitting MS. Design, Setting, and Participants The TY-STOP study, which recruited participants between October 22, 2010, and October 22, 2012, at 8 Italian MS centers (secondary care outpatient clinics) among 124 adult patients who demonstrated no clinical or magnetic resonance imaging MS activity after 24 doses of natalizumab. Interventions Natalizumab, no treatment, i…

AdultMalemedicine.medical_specialtyAdult; Antibodies Monoclonal Humanized; Humans; Italy; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis Relapsing-Remitting; Natalizumab; Prospective Studies; Recurrence; Treatment OutcomeAntibodies Monoclonal HumanizedNatalizumabMultiple Sclerosis Relapsing-RemittingRecurrenceInternal medicineClinical endpointmedicineOutpatient clinicHumansProspective StudiesGlatiramer acetateMultiple Sclerosis Ty-STOP Natalizumabbusiness.industryProgressive multifocal leukoencephalopathyNatalizumabMiddle Agedmedicine.diseaseFingolimodMagnetic Resonance ImagingSurgeryDiscontinuationClinical trialTreatment OutcomeItalySettore MED/26 - NeurologiaNeurology (clinical)businessmedicine.drugJAMA neurology
researchProduct